Effect of drug interaction on anticoagulant strength of warfarin

Abstract

Abstract:

AIM: To provide rational evidence for the administration of warfarin in clinic by investigating the utilization of warfarin in our hospital. METHODS: By retrospective analysis, the prescription of warfarin in our hospital was obtained from November 2016 to February 2017 from the system for clinical pharmacist. The general situation of the inpatient, the diagnosis of disease, the use of warfarin, and the combination of drugs and the number of International Normalized Ratio (INR) were statistically and descriptively analyzed. RESULTS:In this investigation, 200 patients were included, of whom 53% were males and 47% were females with an average age of (55.28±13.56) years. Only 21% of the average INR values reached the predicted range (2<INR<3) during hospitalization and the average dose of warfarin was (2.62±0.60) mg. In patients with INR＜2, there were 66.92% of patients combined with more than one kind of drugs, which decreased the effect of warfarin. In patients with INR＞3, there were 80% of patients combined with more than one kind of drugs, which increased the effect of warfarin. CONCLUSION:The rate of warfarin compliance is low and the warfarin-drug interactions exert a great influence on the patients whose INR value did not reach the predicted range. Thus, to keep the drug safety of patients, more attention should be paid on drug interactions and direct personalized medicine using professional knowledge of pharmacy.

Key words: warfarin, drug interaction, anticoagulant strength, rational administration of drugs

CLC Number:

R969

YANG Rui, XU Haisha, ZHANG Zanling, QU Jian, LI Juan, PENG Shiqi, DAI Yuxin, QU Qiang. Effect of drug interaction on anticoagulant strength of warfarin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1426-1431.

References

［1］Millar CM, Laffan MA. Drug therapy in anticoagulation: which drug for which patient［J］? Clin Med, 2017, 17(3): 233-244.
［2］Jacobs A, Bassa F, Decloedt EH. A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa［J］. Cardiovasc J Afr, 2017, 28: 1-4.
［3］柯鹍鹏，刘寅强，杨鸿生. 华法林抗凝剂量与其影响因素的研究进展［J］. 医学综述，2013, 19(11): 1006-2084.
［4］洪珊珊, 张进华, 林志强. 64例国际标准化比值异常升高的原因分析［J］. 黑龙江医学，2016, 8(3): 751-752.
［5］徐鹏, 张国柱. 基于药品说明书分析住院患者华法林的药物相互作用及抗凝强度［J］. 中国药师，2016, 19(11): 2113-2115.
［6］孙艳, 田方圆, 裴斐. 药物相互作用致患者服用华法林期间INR异常升高的处方分析［J］. 中国应用与监测，2016, 12(4): 239-241.
［7］中华医学会心血管病学分会，中国老年学学会. 华法林抗凝作用的中国专家共识［J］. 中华内科杂志，2013, 52(1): 76-82.
［8］张喆, 罗梦林, 田敏, 等. 华法林抗凝患者的抗凝现状调查及分析［J］. 中国医院药学杂志, 2014, 32(2): 127-130.
［9］韩爽, 毛齐学, 刘文秀, 等. 影响凝血酶原时间的国际标准化比值准确性的因素分析［J］. 中国当代医药, 2013, 20(14): 114-115.
［10］张瑜, 游鹏程, 郑秋山. 115例华法林临床应用调查分析［J］. 中国药物警戒, 2011, 8(9): 524-527.
［11］肖青. 氯吡格雷联合低分子肝素钙治疗短暂性脑缺血发作的临床疗效［J］. 现代仪器与医疗, 2014, 9(4): 75-77.
［12］赵真, 包正军, 许宏伟, 等. 氯吡格雷与阿司匹林联合应用在急性脑梗死治疗中的疗效评定［J］. 国际神经病学神经外科学杂志, 2012, 39(2): 117-120.
［13］师树田, 聂绍平. 非ST段抬高型急性冠脉综合征患者的抗血小板治疗--2014年美国NSTE-ACS治疗指南的更新［J］. 中国医刊, 2015, 10(6): 21-24.
［14］Mattichak SJ, Reed PS, Gallagher MJ, et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction［J］. J Interv Cardiol, 2005, 18(3): 163-166.
［15］Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting in associated with a significant risk of bleeding［J］. J Invasive Cardiol, 2006, 18(4): 162-164.
［16］扈秀丽,李予文. 华法林与阿司匹林和氯吡格雷三重抗栓治疗的安全性［J］. 中国心脏起搏与心电生理杂志, 2012, 26(1): 58-60.
［17］牟宁波. 华法林抗凝血作用的影响因素分析［J］. 中国处方药, 2016, 14(4): 16-17.

[1]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[2]	LIU Xiumei, GUO Qianqian, FANG Yuan, CHEN Nan, QI Qi. Pharmaceutical care of patients with antithrombotic therapy after transjugular intrahepatic portal shunt [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 556-560.
[3]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[4]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[5]	LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang. Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273.
[6]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[7]	WEN Dusu, WANG Yi, SUN Jianjun. Comparison of Bayesian method and multiple linear regression method in predicting warfarin dose model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 33-38.
[8]	LIU Lu, CHEN Xiaoyan. Current status of clinical drug-drug interactions research of innovative small molecule drugs in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
[9]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[10]	ZHOU Han, LIU Xiaodong. Application of physiologically based pharmacokinetic model in drug development and several questions being thought [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913.
[11]	SUN Bo, FU Shujun, CHEN Guiliang, LI Li. Applications of Drug Interaction Study in New Drug Development and Regulartory Decision-making [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1095-1102.
[12]	ZHAI Yu, YANG Jin. Effects of dietary vitamin K on the stability of warfarin anticoagulation therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 709-715.
[13]	YANG Lu, WEI Bin, ZHANG Liping, BI Shanshan, LU Wei. Response surface model to optimize the concentration range of propofol and remifentanil [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 413-420.
[14]	WU Qiaoyu, YUAN Hong, LU Yao. Evaluation of the effects of resveratrol on the activity human cytochrome P450 through combined probe method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 426-432.
[15]	SHA Bijun, ZHOU Sufeng, WANG Lu, ZHAO Yuqing, CHEN Xijing, SHAO Feng. Methods and progress of clinical research on drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1037-1045.